Literature DB >> 24947832

Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways.

Lauran Reyniers1, Maria Grazia Del Giudice2, Laura Civiero3, Elisa Belluzzi3, Evy Lobbestael1, Alexandra Beilina4, Giorgio Arrigoni5,6, Rita Derua7, Etienne Waelkens7, Yan Li8, Claudia Crosio2, Ciro Iaccarino2, Mark R Cookson4, Veerle Baekelandt1, Elisa Greggio3, Jean-Marc Taymans1.   

Abstract

Genetic studies show that LRRK2, and not its closest paralogue LRRK1, is linked to Parkinson's disease. To gain insight into the molecular and cellular basis of this discrepancy, we searched for LRRK1- and LRRK2-specific cellular processes by identifying their distinct interacting proteins. A protein microarray-based interaction screen was performed with recombinant 3xFlag-LRRK1 and 3xFlag-LRRK2 and, in parallel, co-immunoprecipitation followed by mass spectrometry was performed from SH-SY5Y neuroblastoma cell lines stably expressing 3xFlag-LRRK1 or 3xFlag-LRRK2. We identified a set of LRRK1- and LRRK2-specific as well as common interactors. One of our most prominent findings was that both screens pointed to epidermal growth factor receptor (EGF-R) as a LRRK1-specific interactor, while 14-3-3 proteins were LRRK2-specific. This is consistent with phosphosite mapping of LRRK1, revealing phosphosites outside of 14-3-3 consensus binding motifs. To assess the functional relevance of these interactions, SH-SY5Y-LRRK1 and -LRRK2 cell lines were treated with LRRK2 kinase inhibitors that disrupt 14-3-3 binding, or with EGF, an EGF-R agonist. Redistribution of LRRK2, not LRRK1, from diffuse cytoplasmic to filamentous aggregates was observed after inhibitor treatment. Similarly, EGF induced translocation of LRRK1, but not of LRRK2, to endosomes. Our study confirms that LRRK1 and LRRK2 can carry out distinct functions by interacting with different cellular proteins. LRRK1 and LRRK2 (leucine-rich repeat kinase) interaction partners were identified by two different protein-protein interaction screens. These confirmed epidermal growth factor receptor (EGR-R) as a LRRK1-specific interactor, while 14-3-3 proteins were LRRK2-specific. Functional analysis of these interactions and the pathways they mediate shows that LRRK1 and LRRK2 signaling do not intersect, reflective of the differential role of both LRRKs in Parkinson's disease.
© 2014 International Society for Neurochemistry.

Entities:  

Keywords:  LRRK1; LRRK2; Parkinson's disease; protein-protein interactions; signaling networks

Mesh:

Substances:

Year:  2014        PMID: 24947832      PMCID: PMC4272680          DOI: 10.1111/jnc.12798

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  57 in total

Review 1.  The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.

Authors:  Jing Li; Joanna Soroka; Johannes Buchner
Journal:  Biochim Biophys Acta       Date:  2011-09-16

Review 2.  Structure and mechanism of the Hsp90 molecular chaperone machinery.

Authors:  Laurence H Pearl; Chrisostomos Prodromou
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

3.  A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases.

Authors:  Aaron Gajadhar; Abhijit Guha
Journal:  Biotechniques       Date:  2010-02       Impact factor: 1.993

4.  The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2.

Authors:  Lizhen Wang; Chengsong Xie; Elisa Greggio; Loukia Parisiadou; Hoon Shim; Lixin Sun; Jayanth Chandran; Xian Lin; Chen Lai; Wan-Jou Yang; Darren J Moore; Ted M Dawson; Valina L Dawson; Gabriela Chiosis; Mark R Cookson; Huaibin Cai
Journal:  J Neurosci       Date:  2008-03-26       Impact factor: 6.167

5.  Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway.

Authors:  Kristoffer Haugarvoll; Mathias Toft; Owen A Ross; Linda R White; Jan O Aasly; Matthew J Farrer
Journal:  Neurosci Lett       Date:  2007-02-12       Impact factor: 3.046

6.  Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.

Authors:  Renée Vancraenenbroeck; Evy Lobbestael; Stephen D Weeks; Sergei V Strelkov; Veerle Baekelandt; Jean-Marc Taymans; Marc De Maeyer
Journal:  Biochim Biophys Acta       Date:  2012-01-11

7.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

8.  Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment.

Authors:  Christian L Klein; Giorgio Rovelli; Wolfdieter Springer; Christoph Schall; Thomas Gasser; Philipp J Kahle
Journal:  J Neurochem       Date:  2009-08-27       Impact factor: 5.372

9.  Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.

Authors:  Shinji Higashi; Darren J Moore; Ryoko Yamamoto; Michiko Minegishi; Kiyoshi Sato; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Yoshiko Furukawa; Hiroaki Hino; Kenji Kosaka; Piers C Emson; Keiji Wada; Valina L Dawson; Ted M Dawson; Heii Arai; Eizo Iseki
Journal:  J Neuropathol Exp Neurol       Date:  2009-09       Impact factor: 3.685

Review 10.  The function of ROCO proteins in health and disease.

Authors:  Patrick A Lewis
Journal:  Biol Cell       Date:  2009-03       Impact factor: 4.458

View more
  31 in total

Review 1.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 2.  Proteomics; applications in familial Parkinson's disease.

Authors:  Yan Li; Mark R Cookson
Journal:  J Neurochem       Date:  2019-07-09       Impact factor: 5.372

3.  LRRK2 Promotes Tau Accumulation, Aggregation and Release.

Authors:  Patrícia Silva Guerreiro; Ellen Gerhardt; Tomás Lopes da Fonseca; Mathias Bähr; Tiago Fleming Outeiro; Katrin Eckermann
Journal:  Mol Neurobiol       Date:  2015-05-27       Impact factor: 5.590

Review 4.  The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.

Authors:  Rebekah G Langston; Iakov N Rudenko; Mark R Cookson
Journal:  Biochem J       Date:  2016-02-01       Impact factor: 3.857

5.  Rare variants in MC1R/TUBB3 exon 1 are not associated with Parkinson's disease.

Authors:  Oswaldo Lorenzo-Betancor; Zbigniew K Wszolek; Owen A Ross
Journal:  Ann Neurol       Date:  2016-01-19       Impact factor: 10.422

6.  Biophysical Characterization of Essential Phosphorylation at the Flexible C-Terminal Region of C-Raf with 14-3-3ζ Protein.

Authors:  Anirban Ghosh; Bhisma Narayan Ratha; Nilanjan Gayen; Kamal H Mroue; Rajiv K Kar; Atin K Mandal; Anirban Bhunia
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

Review 7.  A visual review of the interactome of LRRK2: Using deep-curated molecular interaction data to represent biology.

Authors:  Pablo Porras; Margaret Duesbury; Antonio Fabregat; Marius Ueffing; Sandra Orchard; Christian Johannes Gloeckner; Henning Hermjakob
Journal:  Proteomics       Date:  2015-03-21       Impact factor: 3.984

Review 8.  Cellular processes associated with LRRK2 function and dysfunction.

Authors:  Rebecca Wallings; Claudia Manzoni; Rina Bandopadhyay
Journal:  FEBS J       Date:  2015-05-09       Impact factor: 5.542

Review 9.  Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism.

Authors:  Jean-Marc Taymans; Veerle Baekelandt
Journal:  Front Genet       Date:  2014-11-07       Impact factor: 4.599

10.  In silico comparative analysis of LRRK2 interactomes from brain, kidney and lung.

Authors:  Amrita Verma; Kirsten Ebanks; Chi-Yee Fok; Patrick A Lewis; Conceicao Bettencourt; Rina Bandopadhyay
Journal:  Brain Res       Date:  2021-04-26       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.